will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50 mg/m2) for 6 weeks, followed by surgery. FTD/TPI will be self-administered (in tablet form) twice daily by study participants and documented in
Search Results
,040 cGy will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50 mg/m 2 ) for 6 weeks, followed by surgery. FTD/TPI will be self-administered (in tablet form) twice daily by study participants and
/TPI (35 mg/m 2 twice daily) and oxaliplatin (85 mg/m 2 ) before undergoing concurrent chemoradiation (standard-of-care radiation dose of 5,040 cGy will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50
dose of 5,040 cGy will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50 mg/m2) for 6 weeks, followed by surgery. FTD/TPI will be self-administered (in tablet form) twice daily by study participants
Presented by: Deborah K. Armstrong
The study’s first arm was placebo + carboplatin/paclitaxel followed by placebo as maintenance. Arm 2 was veliparib + carboplatin/paclitaxel followed by placebo. Arm 3 was veliparib + carboplatin/paclitaxel followed by veliparib maintenance. An
/TPI (35 mg/m 2 twice daily) and oxaliplatin (85 mg/m 2 ) before undergoing concurrent chemoradiation (standard-of-care radiation dose of 5,040 cGy will be used at all participating study sites) with carboplatin (area under the curve 2) and paclitaxel (50
Jeffrey J. Wargo, David R. Carr, Jose A. Plaza, and Claire F. Verschraegen
of PD-L1. The combination of carboplatin and paclitaxel was administered every 3 weeks for 4 cycles, but the disease progressed in the right lung. She was then referred to Ohio State University, and 200 mg of pembrolizumab was administered
Daniel Morgensztern and Ramaswamy Govindan
randomised controlled trial . Lancet Oncol 2006 ; 7 : 719 – 727 . 13. Strauss GM Herndon J Maddaus MA . Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung
proposals for afatinib have been awarded funding: Matthew Fury, MD, PhD, Memorial Sloan-Kettering Cancer Center, “Phase I Study of Induction Chemotherapy with Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage III/IVB HPV Associated
, Genentech/Roche) in metastatic breast cancer. The recommendation is as follows: Bevacizumab in combination with paclitaxel is an appropriate therapeutic option for metastatic breast cancer with the evidence designation 2A. The following footnote
